Potential use of the ATWLPPR heptapeptide as a molecular imaging agent of tumor angiogenesis
DOI:
https://doi.org/10.35954/SM2019.38.1.4Keywords:
ATWLPPR, HYNIC, Oncological Molecular Imaging, Breast Neoplasms, Technetium Tc 99m SestamibiAbstract
Molecular Imaging comprises the visualization, characterization and measurement of biological processes at the molecular and cellular level in humans or other living beings. This discipline includes 2 or 3 dimension imaging and their quantification over time. Techniques used include, among others, nuclear medicine. This has led to the definition of molecular imaging agents, as probes used to visualize, characterize and measure biological processes in living systems, where endogenous and exogenous molecules can be used. In the present paper we propose to develop and optimize the gamma emitting radionuclide labeling, 99m-Technetium, of the anti-angiogenic heptapeptide, the ATWLPPR, in order to assess its potential use as a molecular imaging agent of the angiogenic processes associated with breast cancer. For this, both HYNIC-ATWLPPR and HYNIC-GSGATWLPPR were commercially purchased. The 99mTclabeling was performed at 50 °C in the presence of different co-ligands including Tricine, Ethylenediamine diacetic acid, Tricine/Ethylenediamine diacetic acid and Tricine/Nicotinic acid. Labeling conditions (pH, coligands concentration of reducing agent (tin chloride), temperature and reaction time) were optimized in order to standardize the procedure.
Radiochemical purities were assessed by HPLC.
Downloads
Metrics
References
(1) Mankoff DA. A definition of molecular imaging. J Nucl Med 2007; 48(6):18N-21N.
(2) Weissleder R, Mahmood U. Molecular Imaging. Radiology 2001; 219:316-33.
(3) Willmann JK, van Bruggen N, Dinkelborg LM, Gambhir SS. Molecular imaging in drug development. Nat Rev Drug Discov 2008; 7(7):591-607.
(4) James ML, Gambhir SS. A molecular imaging primer: modalities, imaging agents, and applications. Physiol Rev 2012; 92:897-965
(5) Nichol C, Kim EE. Molecular imaging and gene therapy. J Nucl Med 2001; 42(9):1368-1374.
(6) Weissleder R. olecular imaging in cancer. Science 2006; 312(5777):1168-71.
(7) Buist DS, Porter PL, Lehman C, Taplin SH, White E. Factors contributing to mammography failure in women aged 40-49 years. J Natl Inst 2004; 96:1432-1440.
(8) Avril N, Menzel M, Dose J, Schelling M, Weber W, Jänicke F, et al. Glucose metabolism of breast cancer assessed by 18-FDG PET: histologic and immunohistochemical tissue analysis. J Nucl Med 2001; 42:9-16.
(9) Avril N, Rosé CA, Schelling M, Dose J, Kuhn W,Bense S,et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18:3495-3502.
(10) Isasi CR, Moadel RM, Blaufox MD. A metaanalysis of FDG PET for the evaluation of breast cancer recurrence and metastases. Breast Cancer Treat 2005; 90:105-12.
(11) Lonneux M, Borbath I, Berlière M, Kirkove C, Pauwels S. The place of whole-body PET FDG for the diagnosis of distant recurrence of breast cancer. Clin Positron Imaging 2000; 3:45-49.
(12) Dilworth JR, Parrott JS. The biomedical chemistry of technetium and rhenium. Chem Soc Rev 1988; 27:43-55.
(13) Carmeliet P; Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407:249-57.
(14) Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438:932-936.
(15) Ferrara N. Role of vascular endothelial growth factor in physiologic and patholgic angiogenesis: therapeutic implications. Semin Oncol 2002; 29(6):10-14.
(16) Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9(6):669-676.
(17) Dvorak HF. Angiogenesis: update 2005. Thromb Haemost 2005; 3:1835-42.
(18) Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9:653-60.
(19) Dvorak HF, Brown LF, Detmar M, Dvorak AM. Vascular permeability factor/vascular endothelial growth factor and the significance on microvascular hyperpermeability in angiogenesis. Curr Top Microbiol Inmunol 1999; 237:97-132.
(20) Partanen TA, Paavonen K. Lymphatic versus blood vascular endothelial growth factors and receptors in humans. Microsc Res Tech 2001; 5:108-121.
(21) Ellis LM. The role of neuropilins in cancer. Mol Cancer Ther 2006; 5(5):1099-107.
(22) Lampropoulou A, Ruhrberg C. Neuropilin regulation of angiogenesis. Biochem Soci Trans 2014; 42(6):1623-28.
(23) Miao HQ, Lee P, Lin H, Soker S, Klagsbrun M. Neuropilin-1 expression by tumor cells promotes tumor angiogenesis and progression. FASEB Journal 2000; 14(15):2532-39.
(24) Fakhari M, Pullirsch D, Abraham D, Paya K,Hofbauer R,Holzfeind P,et al. Selective upregulation of vascular endothelial growth factors receptors neuropilin-1 and -2 in human neuroblastoma. Cancer 2002; 94(1):258-63.
(25) Bachelder RE, Crago A, Chung J, Wendt MA, Shaw LM, Robinson G, et al. Vascular endothelial growth factor is an autocrine survival factor for neuropilin-expressing breast carcinoma cells. Cancer Res 2001; 61(15):5736-40.
(26) Barr MP, Byrne AM, Duffy AM, Condron CM, Devocelle M, Harriott P, et al. A peptide corresponding to the neuropilin-1-biniding site on VEGF(165) induces apoptosis of neuropilin-1- expressing breast tumor cells. British J Cancer 2005; 92(2):328-33.
(27) Tas F, Duranyildiz D, Oguz H, Camlica H, Yasasever V, Topuz E. Circulating serum levels of angiogenic factors and vascular endohtelial growth factors receptors 1 and 2 in melanoma patients. Melanoma Res 2006; 16(5):405-11.
(28) Ingber D,Fujita T,Kishimoto S,Sudo K,Kanamaru T, Brem H, et al. Synthetic analogues of fumagilin that inhibit angiogenesis and supress tumour growth. Nature 1990; 348:555-7
(29) Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-42.
(30) Binétruy-Tournaire R, Demangel C, Malavaud B, Vassy R, Rouyre S, Kraemer M, et al. Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis. EMBO J 2000; 19(7):1525-33.
(31) Perret GY, Starzec A, Hauet N, Vergote J, Le Pecheur M, Vassy R, et al. In vitro evaluation and biodistribution of a 99mTc-labelled anti-VEGF peptide targeting neuropilin-1. Nucl Med Biol 2004; 31:575-81.
(32) Starzec A, Vassy R, Martin A, Lecouvey M, Di Benedetto M, Crépin M, et al. Antiangiogenic and antitumor activities of peptide inhibiting the vascular endothelial growth factor binding to neuropilin-1. Life Sci 2006; 79:2370-81.
(33) Tirand L, Frochot C, Vanderesse R, Thomas N, Trinquet E, Pinel S, et al. A peptide competing with VEGF165 binding on neuropilin-1 targeting of a chlorine-type photosensitizer and potentiates its photodynamic activity in human endothelial cells. J Control Res 2006; 111:153-64.
(34) Jurisson S, Berning D, Jia W, Ma D. Coordination Compounds in Nuclear Medicine. Chem Rev 1993; 93(3):1137-56.
(35) Dilworth JR, Parrottb JS. The biomedical chemistry of technetium and rhenium. Chem Soc Rev 1988; 27:43-55.
(36) Camacho X, Machado CL, García MF, Fernández M, Oddone N, Benech J. Tocilizumab labeling with 99mTechnetium via HYNIC as a molecular diagnostic agent for Multiple Myeloma. Anticancer Agents Med Chem 2017; 17(9):1267-1277.
(37) Camacho X, Machado CL, García MF, Gambini JP, Banchero A, Fernández M, et al. Technetium99m- or Cy7-Labeled Rituximab as an Imaging Agent for Non-Hodgkin Lymphoma. Oncology 2017; 15(92):229-42.
(38) Calzada V, García MF, Alonso-Martínez LM, Camacho X, Goicochea E, Fernández M, et al. Fab(nimotuzumab)-HYNIC-99mTc: Antibody fragmentation for molecular imaging agents. Anticancer Agents Med Chem 2016; 16(9):1184-9.
(39) Camacho X, García MF, Calzada V, Fernández M, Alonso O Gambini JP, et al. 99mTc-labeled Bevacizumab vía HYNIC for Imaging of Melanoma. J Anal Oncology 2014; 3:53-64.
(40) García MF, Calzada V, Camacho X, Goicochea E, Gambini JP, Quinn TP, et al. Microwave-assisted Synthesis of HYNIC Protected Analogue for 99mTc Labeled Antibody. Curr Radiopharm 2014; 7(2):84-90.
(41) Hnatowich J, Virzi F, Fogarasi M, Rusckowski M, Winnard P Jr. Can a cysteine challenge assay predict the in vivo behavior of 99mTc-labeled antibodies? Nucl Med Biol 1994; 21(8):1035-44.
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Ximena Camacho, Carolina Perroni, María Fernanda García, Juan Pablo Gambini,Marcelo Fernández y Pablo Cabral. The author retains his copyright and assigns to the journal the right of first publication of his work, which will be simultaneously subject to the Creative Commons Attribution 4.0 International License that allows sharing the work as long as the initial publication in this journal is indicated.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Until 2024 we use the Creative Commons Attribution/NonCommercial Attribution 4.0 International License https://creativecommons.org/licenses/by-nc/4.0/deed.es. Which states that: you are free to share, copy and redistribute the material in any medium or format, as well as to adapt, remix, transform and build upon the material. Under the following terms:
Attribution: you must give proper credit , provide a link to the license, and indicate if changes have been made . You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
NonCommercial: you may not use the material for commercial purposes.
As of 2025 authors retain their copyright and assign to the journal the right of first publication of their work, which shall simultaneously be subject to the license https://creativecommons.org/licenses/by-nc-sa/4.0/deed.es that permits sharing, copying and redistribution of the material in any medium or format provided that initial publication in this journal is indicated. Adapt, remix, transform and build upon the material. If you remix, transform, or build from the material, you must distribute your contribution under the same license as the original and may not make use of the material for commercial purposes.
Under the following terms:
1. Attribution: you must give proper credit, provide a link to the license, and indicate whether changes have been made. You may do so in any reasonable manner, but not in such a way as to suggest that you or your use is endorsed by the licensor.
2. NonCommercial: you may not use the material for commercial purposes.
3. ShareAlike: if you remix, transform or build upon the material, you must distribute your contribution under the same license as the original.
PlumX Metrics
/
